Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.80 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
| ▸ | BLVRB | P30043 | 1/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.80 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.80 |
| ▸ | PPID | Q08752 | 1/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655618 | 1.00 | XDH (0.80) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2635992 | 0.92 | XDH (0.83) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL22745328 | 0.92 | XDH (0.76) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL19523342 | 0.91 | XDH (0.65) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL19523355 | 0.90 | XDH (0.68) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL458064 | 0.90 | XDH (0.80) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL22745409 | 0.90 | XDH (0.73) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL29103934 | 0.90 | XDH (0.73) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL29323469 | 0.89 | XDH (0.81) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL30050323 | 0.89 | XDH (0.75) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772137-B | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117924211-A | Preparation method of febuxostat | 哈药集团技术中心 | 2024-04-26 | — | — | CN | claimed |
| CN-112142685-B | Improved method for synthesizing febuxostat key intermediate | 北京鑫开元医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115772137-A | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-115561373-A | Method for detecting febuxostat content and related substances | 河北冀衡药业股份有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-109293597-B | Preparation method of febuxostat | 安徽省庆云医药股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-109320474-B | Preparation method of febuxostat | 昆明源瑞制药有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-109503513-B | One-pot synthesis method of febuxostat intermediate | 嘉实（湖南）医药科技有限公司 | 2020-09-25 | — | — | CN | claimed |
| CN-111499593-A | Synthesis process of febuxostat | 峨眉山宏昇药业股份有限公司 | 2020-08-07 | — | — | CN | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| US-20130165662-A1 | PREPARATION OF FEBUXOSTAT | DR. REDDY'S LABORATORIES, INC. (US) | 2013-06-27 | — | — | US | claimed |
| EP-2563768-A2 | PREPARATION OF FEBUXOSTAT | Dr. Reddy's Laboratories Ltd. (IN) | 2013-03-06 | — | — | EP | claimed |
| EP-2536699-A2 | SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF | Cadila Healthcare Limited (IN) | 2012-12-26 | — | — | EP | claimed |
| WO-2012131590-A1 | AN IMPROVED PROCESS FOR PREPARATION OF FEBUXOSTAT AND ITS POLYMORPHIC CRYSTALLINE FORM C THEREOF | SANDOZ AG (CH) | 2012-10-04 | — | — | WO | claimed |
| WO-2012048861-A1 | A NOVEL FEBUXOSTAT CRYSTALLINE FORM AND THE PROCESS FOR THE PREPARATION THEREOF | GADOR S.A. (AR) | 2012-04-19 | — | — | WO | claimed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | claimed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | claimed |
| WO-2011139886-A2 | PREPARATION OF FEBUXOSTAT | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-11-10 | — | — | WO | claimed |
| WO-2011101867-A2 | SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-08-25 | — | — | WO | claimed |
| CN-102002016-A | Improvement method for synthesizing febuxostat | BEIJING MEIDI KANGXIN MEDICAL TECHNOLOGY CO LTD | 2011-04-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165662-A1 | PREPARATION OF FEBUXOSTAT | FIP1L1, FECH, FBP1 | XDH 36/4885TARBP2 2072/4885ABCC4 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.